Drug Combination Details
| General Information of the Combination (ID: C53703) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Sulindac sulfone Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| In-vivo Model | Aberrant crypt foci (ACF) were induced male Wistar rats (6-week old) with DMH. | |||||
| Experimental
Result(s) |
Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer. Expert Opin Investig Drugs. 2010 Apr;19 Suppl 1:S117-24. | |||
